Syncardia全人工心脏植入后的心脏移植
Heart transplantation after SynCardia total artificial heart implantation.
作者信息
Morshuis Michiel, Rojas Sebastian V, Hakim-Meibodi Kavous, Razumov Artyom, Gummert Jan F, Schramm René
机构信息
Clinic for Thoracic- and Cardiovascular Surgery, Heart and Diabetes Centre North Rhine Westphalia, Bad Oeynhausen, Germany.
出版信息
Ann Cardiothorac Surg. 2020 Mar;9(2):98-103. doi: 10.21037/acs.2020.03.12.
BACKGROUND
The SynCardia total artificial heart (TAH) is the only approved TAH device. This report summarizes our single-center experience with the SynCardia TAH with particular focus on the outcome after subsequent heart transplantation.
METHODS
We retrospectively analysed the outcome of all transplanted SynCardia TAH patients at our center between 2001 and 2019 in comparison to transplanted left ventricular assist device (LVAD) and biventricular assist device (BVAD) patients and to transplanted patients without prior durable mechanical circulatory support (non-MCS).
RESULTS
Only a fraction (n=69; 37.3%) of all SynCardia TAH patients (n=193) were transplanted. The majority (81.2%) of those were in high-urgency status at the time of transplantation. Survival in transplanted SynCardia TAH patients was significantly poorer when compared to LVAD-, BVAD- and non-MCS patients (P=0.008).
CONCLUSIONS
Heart transplantation in SynCardia TAH patients requires distinct risk stratification to improve outcomes.
背景
SynCardia全人工心脏（TAH）是唯一获批的TAH设备。本报告总结了我们单中心使用SynCardia TAH的经验，特别关注后续心脏移植后的结果。
方法
我们回顾性分析了2001年至2019年间在我们中心接受移植的所有SynCardia TAH患者的结果，并与接受移植的左心室辅助装置（LVAD）和双心室辅助装置（BVAD）患者以及未接受过持久机械循环支持（非MCS）的移植患者进行比较。
结果
所有SynCardia TAH患者（n = 193）中只有一小部分（n = 69；37.3%）接受了移植。其中大多数（81.2%）在移植时处于高紧急状态。与LVAD、BVAD和非MCS患者相比，接受移植的SynCardia TAH患者的生存率明显更低（P = 0.008）。
结论
SynCardia TAH患者的心脏移植需要进行明确的风险分层以改善结果。
Zotero 插件